Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement
MWN-AI** Summary
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW), a pioneering medical device firm based in Israel, reported that it received a notification from Nasdaq on February 9, 2026. This notification indicated that the company is currently not in compliance with the minimum bid price requirement mandated by Nasdaq Listing Rule 5550(a)(2). Specifically, Inspira’s ordinary shares have traded below the $1.00 threshold for the last 30 consecutive business days.
While the receipt of the Notification Letter does not immediately affect the trading status of Inspira’s ordinary shares, which will continue to be traded on The Nasdaq Capital Market under the symbol "IINN", the company is now under a compliance period that lasts until August 10, 2026. During this span, to regain compliance, Inspira must achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
Should Inspira fail to meet the requirements by the end of the compliance period, there is a possibility for a second 180-day period to regain compliance, provided the company meets other necessary listing standards. This may include actions such as a reverse share split to remedy the deficiency.
Inspira Technologies is recognized for its innovative life-support and blood monitoring solutions, with products like the FDA-cleared INSPIRA™ ART100 system and the upcoming INSPIRA ART500 system. The company reassured stakeholders that it would actively monitor its stock price and evaluate strategies to regain adherence to Nasdaq listing requirements.
This disclosure aligns with Nasdaq Listing Rule 5810(b), which mandates timely communication regarding compliance notifications. Further details about the potential risks can be found in the company's annual report filed with the SEC.
MWN-AI** Analysis
Inspira Technologies (NASDAQ: IINN) is currently navigating a critical phase following its recent notification from Nasdaq regarding non-compliance with the minimum bid price requirement, which necessitates proactive measures from both the company and investors. With its shares trading below $1.00 for the past 30 business days, there’s a pressing need for vigilant monitoring and strategic decision-making within a 180-day compliance period.
Investors should closely observe management’s response strategies during this compliance window. The potential for a reverse stock split is a significant consideration that may impact shareholdings and future trading behavior. If executed, this strategy could stabilize the stock price, provided it garners sufficient market confidence.
Furthermore, it’s pivotal to evaluate the company's fundamentals. Inspira’s innovative product offerings, such as the INSPIRA™ ART100 and the forthcoming ART500 system, position it competitively within the evolving MedTech landscape. The company's specialization in real-time blood monitoring solutions addresses growing healthcare demands, suggesting a potential rebound in investor sentiment if operational execution aligns with market needs.
Moreover, the regulatory environment surrounding FDA-cleared devices presents both a challenge and opportunity. Scrutiny from the market will be focused on Inspira's ability to maintain compliance, successfully navigate listing requirements, and leverage its intellectual property in a rapidly changing medical technology sector.
From a market perspective, current conditions reflect a cautious buy-in opportunity for investors who possess a higher risk appetite, emphasizing the importance of due diligence and an assessment of the company's long-term growth trajectory. However, for conservative investors, it might prove prudent to adopt a wait-and-see approach until a clearer path to compliance and stock stability emerges.
In conclusion, while Inspira Technologies showcases promising technological advancements, the need for careful navigation through regulatory requirements and market perceptions remains paramount to ensure it does not face delisting by Nasdaq.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
RA'ANANA, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on February 9, 2026, notifying the Company that it is not currently in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s ordinary shares (“Ordinary Shares”) was below $1.00 per share for the last 30 consecutive business days.
The Notification Letter has no immediate effect on the listing or trading of the Company’s Ordinary Shares, which will continue to trade on The Nasdaq Capital Market under the symbol “IINN.”
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a compliance period of 180 calendar days, or until August 10, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s Ordinary Shares must be at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period.
If the Company does not regain compliance by August 10, 2026, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effectuating a revere share split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.
The Company intends to monitor the closing bid price of its Ordinary Shares between now and August 10, 2026, and intends to consider available options to cure the deficiency regain compliance with the Nasdaq minimum bid price requirement within the Compliance Period.
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ability to regain compliance with the Nasdaq minimum bid price requirement within the applicable Compliance Period, its intention to monitor the trading price of its Ordinary Shares, and its consideration of available options to regain compliance with Nasdaq listing requirements. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ**
What specific operational strategies does Inspira Technologies OXY B.H.N. Ltd. (IINN) plan to implement during the 180-day Compliance Period to regain compliance with Nasdaq's minimum bid price requirement?
Can Inspira Technologies OXY B.H.N. Ltd. (IINN) provide details on any upcoming product developments that might positively influence its stock price and improve compliance with Nasdaq requirements?
How does Inspira Technologies OXY B.H.N. Ltd. (IINN) intend to leverage its existing product portfolio, such as the INSPIRA ART100 and HYLA, to boost investor confidence and enhance its share price?
In the event that Inspira Technologies OXY B.H.N. Ltd. (IINN) does not regain compliance by August 10, 2026, what alternative strategies does the company have to mitigate the potential impact of delisting from Nasdaq?
**MWN-AI FAQ is based on asking OpenAI questions about Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN).
NASDAQ: IINN
IINN Trading
-3.68% G/L:
$0.5711 Last:
84,480 Volume:
$0.594 Open:
